NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

Company Overview

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $0.62 to $0.65
• 50-Day Range: $0.49 to $0.81
• 52-Week Range: $0.36 to $9.08
• Volume: 81,152 shs
• Average Volume: 103,839 shs
• Market Capitalization: $3.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.85
• Consensus Rating: Buy

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

NovaBay Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NovaBay Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($3.26) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovaBay Pharmaceuticals has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NBY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovaBay Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NovaBay Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NBY.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for NBY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed this year?

NovaBay Pharmaceuticals' stock was trading at $0.6010 at the beginning of 2025. Since then, NBY stock has increased by 4.8% and is now trading at $0.63.
View the best growth stocks for 2025 here.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.32. The firm earned $2.44 million during the quarter, compared to analyst estimates of $2.50 million. NovaBay Pharmaceuticals had a negative net margin of 102.72% and a negative trailing twelve-month return on equity of 7,293.78%.

When did NovaBay Pharmaceuticals' stock split?

NovaBay Pharmaceuticals shares reverse split before market open on Friday, May 31st 2024. The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NBY
• CUSIP: N/A
• CIK: 1389545
• Web: novabay.com
• Phone: 510-899-8800
• Fax: 510-474-1577
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $0.85
• High Stock Price Target: $0.85
• Low Stock Price Target: $0.85
• Potential Upside/Downside: +34.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($53.7178)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,640,000.00
• Net Margins: -102.72%
• Pretax Margin: -99.12%
• Return on Equity: -7,293.78%
• Return on Assets: -158.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $14.73 million
• Price / Sales: 0.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 4,890,000
• Free Float: 4,881,000
• Market Cap: $3.08 million
• Optionable: Not Optionable
• Beta: 0.67